{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T22:48:22Z","timestamp":1775688502401,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,8,27]],"date-time":"2011-08-27T00:00:00Z","timestamp":1314403200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s00280-011-1724-7","type":"journal-article","created":{"date-parts":[[2011,8,26]],"date-time":"2011-08-26T07:21:05Z","timestamp":1314343265000},"page":"523-531","source":"Crossref","is-referenced-by-count":13,"title":["Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors"],"prefix":"10.1007","volume":"69","author":[{"given":"Elaine T.","family":"Lam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Goel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry J.","family":"Schaaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian F.","family":"Cropp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison L.","family":"Hannah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiqing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"McCracken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandi I.","family":"Haley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert G.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sridhar","family":"Mani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"Villalona-Calero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,8,27]]},"reference":[{"key":"1724_CR1","doi-asserted-by":"crossref","first-page":"7167","DOI":"10.1158\/1078-0432.CCR-08-0169","volume":"14","author":"PG Morris","year":"2008","unstructured":"Morris PG, Fornier MN (2008) Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 14:7167\u20137172","journal-title":"Clin Cancer Res"},{"key":"1724_CR2","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1158\/1535-7163.MCT-09-0366","volume":"8","author":"EA Perez","year":"2009","unstructured":"Perez EA (2009) Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 8:2086\u20132095","journal-title":"Mol Cancer Ther"},{"key":"1724_CR3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-1-59745-274-8_8","volume-title":"Cancer drug discovery and development: checkpoint responses in cancer therapy","author":"MA Villalona-Calero","year":"2008","unstructured":"Villalona-Calero MA, Schaaf L, Turowski R (2008) Antimicrobule agents. In: Dai W (ed) Cancer drug discovery and development: checkpoint responses in cancer therapy. Humana Press, Tuxedo, pp 177\u2013206"},{"key":"1724_CR4","doi-asserted-by":"crossref","first-page":"v3","DOI":"10.1093\/annonc\/mdm172","volume":"18","author":"T Fojo","year":"2007","unstructured":"Fojo T, Menefee M (2007) Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol 18:v3\u2013v8","journal-title":"Ann Oncol"},{"key":"1724_CR5","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/jnci\/82.15.1247","volume":"82","author":"EK Rowinsky","year":"1990","unstructured":"Rowinsky EK, Cazenave LA, Donehower RC (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247\u20131259","journal-title":"J Natl Cancer Inst"},{"key":"1724_CR6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1146\/annurev.med.48.1.353","volume":"48","author":"EK Rowinsky","year":"1997","unstructured":"Rowinsky EK (1997) The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 48:353\u2013374","journal-title":"Annu Rev Med"},{"key":"1724_CR7","first-page":"789","volume":"2","author":"KL Cheng","year":"2008","unstructured":"Cheng KL, Bradley T, Budman DR (2008) Novel microtubule-targeting agents\u2014the epothilones. Biologics 2:789\u2013811","journal-title":"Biologics"},{"key":"1724_CR8","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1200\/JCO.2004.12.001","volume":"22","author":"S Goodin","year":"2004","unstructured":"Goodin S, Kane MP, Rubin EH (2004) Epothilones: mechanism of action and biologic activity. J Clin Oncol 22:2015\u20132025","journal-title":"J Clin Oncol"},{"key":"1724_CR9","first-page":"505","volume":"2","author":"S Puhalla","year":"2008","unstructured":"Puhalla S, Brufsky A (2008) Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer. Biologics 2:505\u2013515","journal-title":"Biologics"},{"key":"1724_CR10","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/annonc\/mdl315","volume":"18","author":"S Mani","year":"2007","unstructured":"Mani S, McDaid HM, Grossman A et al (2007) Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone. Ann Oncol 18:190\u2013195","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"1724_CR11","doi-asserted-by":"crossref","first-page":"v9","DOI":"10.1093\/annonc\/mdm173","volume":"18","author":"P Fumoleau","year":"2007","unstructured":"Fumoleau P, Coudert B, Isambert N, Ferrant E (2007) Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol 18(Suppl 5):v9\u201315","journal-title":"Ann Oncol"},{"key":"1724_CR12","doi-asserted-by":"crossref","first-page":"9120","DOI":"10.1200\/JCO.2005.03.0981","volume":"23","author":"EH Rubin","year":"2005","unstructured":"Rubin EH, Rothermel J, Tesfaye F et al (2005) Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol 23:9120\u20139129","journal-title":"J Clin Oncol"},{"key":"1724_CR13","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/annonc\/mdp491","volume":"21","author":"P Schmid","year":"2010","unstructured":"Schmid P, Kiewe P, Possinger K et al (2010) Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors. Ann Oncol 21:633\u2013639","journal-title":"Ann Oncol"},{"key":"1724_CR14","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/sj.bjc.6605327","volume":"101","author":"D Arnold","year":"2009","unstructured":"Arnold D, Voigt W, Kiewe P et al (2009) Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial. Br J Cancer 101:1241\u20131247","journal-title":"Br J Cancer"},{"key":"1724_CR15","doi-asserted-by":"crossref","first-page":"8113","DOI":"10.1073\/pnas.131153098","volume":"98","author":"TC Chou","year":"2001","unstructured":"Chou TC, O\u2019Connor OA, Tong WP et al (2001) The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Proc Natl Acad Sci USA 98:8113\u20138118","journal-title":"Proc Natl Acad Sci USA"},{"key":"1724_CR16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10637-007-9068-1","volume":"25","author":"TM Beer","year":"2007","unstructured":"Beer TM, Higano CS, Saleh M et al (2007) Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs 25:565\u2013570","journal-title":"Invest New Drugs"},{"key":"1724_CR17","first-page":"778","volume":"23","author":"B Overmoyer","year":"2005","unstructured":"Overmoyer B, Waintraub S, Kaufman P (2005) Phase II trial of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer. J Clin Oncol 2005 ASCOAnnu Meet Proc 23:778","journal-title":"J Clin Oncol 2005 ASCOAnnu Meet Proc"},{"key":"1724_CR18","unstructured":"Kosan Biosciences I (2004) KOS-1584 investigator\u2019s brochure"},{"key":"1724_CR19","doi-asserted-by":"crossref","first-page":"13157","DOI":"10.1073\/pnas.0804773105","volume":"105","author":"TC Chou","year":"2008","unstructured":"Chou TC, Zhang X, Zhong ZY et al (2008) Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones. Proc Natl Acad Sci USA 105:13157\u201313162","journal-title":"Proc Natl Acad Sci USA"},{"key":"1724_CR20","unstructured":"Zhou y, Zhong Z, Liu F et al. (2005) KOS-1584: a rationally designed epothilone D analog with improved potency and pharmacokinetic (PK) properties. Proc Amer Assoc Cancer Res 46: (Abstract #2535)"},{"key":"1724_CR21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"1724_CR22","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2000.18.3.684","volume":"18","author":"EA Eisenhauer","year":"2000","unstructured":"Eisenhauer EA, O\u2019Dwyer PJ, Christian M, Humphrey JS (2000) Phase I clinical trial design in cancer drug development. J Clin Oncol 18:684\u2013692","journal-title":"J Clin Oncol"},{"key":"1724_CR23","unstructured":"Cancer Therapy Evaluation Program (2006) Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003. http:\/\/ctep.cancer.gov . Accessed 9 Aug 2006"},{"key":"1724_CR24","first-page":"353","volume":"7","author":"H Bazette","year":"1920","unstructured":"Bazette H (1920) An analysis of the time-relations of electrocardiograms. Heart 7:353\u2013370","journal-title":"Heart"},{"key":"1724_CR25","first-page":"2035","volume":"8","author":"HM McDaid","year":"2002","unstructured":"McDaid HM, Mani S, Shen HJ et al (2002) Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res 8:2035\u20132043","journal-title":"Clin Cancer Res"},{"key":"1724_CR26","doi-asserted-by":"crossref","DOI":"10.1201\/b14095","volume-title":"Pharmacokinetics","author":"M Gibaldi","year":"1982","unstructured":"Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York","edition":"2"},{"key":"1724_CR27","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1158\/1078-0432.CCR-0919-03","volume":"10","author":"S Mani","year":"2004","unstructured":"Mani S, McDaid H, Hamilton A et al (2004) Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 10:1289\u20131298","journal-title":"Clin Cancer Res"},{"key":"1724_CR28","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1200\/JCO.2007.12.6557","volume":"25","author":"ES Thomas","year":"2007","unstructured":"Thomas ES, Gomez HL, Li RK et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210\u20135217","journal-title":"J Clin Oncol"},{"key":"1724_CR29","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1200\/JCO.2009.24.4244","volume":"28","author":"JA Sparano","year":"2010","unstructured":"Sparano JA, Vrdoljak E, Rixe O et al (2010) Randomized phase III Trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 28:3256\u20133263","journal-title":"J Clin Oncol"},{"key":"1724_CR30","unstructured":"http:\/\/www.clinicaltrials.gov . In Edition Accessed 31 May 2010"},{"key":"1724_CR31","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1200\/JCO.2008.20.4826","volume":"27","author":"WW Ten Bokkel Huinink","year":"2009","unstructured":"Ten Bokkel Huinink WW, Sufliarsky J, Smit WM et al (2009) Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study. J Clin Oncol 27:3097\u20133103","journal-title":"J Clin Oncol"},{"key":"1724_CR32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1289\/ehp.761343","volume":"13","author":"RL Dixon","year":"1976","unstructured":"Dixon RL (1976) Problems in extrapolating toxicity data for laboratory animals to man. Environ Health Perspect 13:43\u201350","journal-title":"Environ Health Perspect"},{"key":"1724_CR33","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1177\/0091270003254631","volume":"43","author":"I Mahmood","year":"2003","unstructured":"Mahmood I, Green MD, Fisher JE (2003) Selection of the first-time dose in humans: comparison of different approaches based on interspecies scaling of clearance. J Clin Pharmacol 43:692\u2013697","journal-title":"J Clin Pharmacol"},{"key":"1724_CR34","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","volume":"22","author":"S Reagan-Shaw","year":"2008","unstructured":"Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22:659\u2013661","journal-title":"FASEB J"},{"key":"1724_CR35","doi-asserted-by":"crossref","unstructured":"Stopeck A, Moulder S, Jones S et al. (2007) Phase I trial of KOS-1584 (a novel epothilone) using two weekly dosing schedules. J Clin Oncol. 24: (Abstract 2571). ASCO Annual Meeting Proceedings Part I","DOI":"10.1200\/jco.2007.25.18_suppl.2571"},{"key":"1724_CR36","unstructured":"Ixabepilone (Ixempra) (2010) Package Insert. Bristol-Myers Squibb"},{"key":"1724_CR37","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1158\/1078-0432.CCR-07-4151","volume":"14","author":"S Goel","year":"2008","unstructured":"Goel S, Cohen M, Comezoglu SN et al (2008) The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res 14:2701\u20132709","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1724-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-011-1724-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1724-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:11:58Z","timestamp":1638403918000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-011-1724-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,27]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["1724"],"URL":"https:\/\/doi.org\/10.1007\/s00280-011-1724-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,27]]}}}